A case report of de novo immune thrombocytopenic purpura (ITP) following COVID-19-mRNA vaccination: 2-year clinical follow up.

After vaccination with mRNA vaccines, several cases of autoimmune diseases have been reported. We presented a case report of an adult male patient, without any previous report of thrombocytopenia or other hematologic disorders, who developed a chronic paucisymptomatic or mild ITP secondary to SARS-CoV-2 m-RNA vaccine. The patient received the first and second doses of mRNA BNT162b2 vaccine (June/2021), the first booster dose of mRNA-1273 (November/2021), and the second booster dose of mRNA BNT162b2 (June/2022). Thrombocytopenia was documented after each vaccination. After corticoids therapy was implemented, the patient improved. However, cycling thrombocytopenia was documented until August/2023 (mean: 103 x109 platelets/L).

疫苗接种mRNA疫苗后，已有多例自身免疫疾病的报道。本研究呈现了一例成年男性患者的病例报告，该患者此前未曾有血小板减少症或其他血液学疾病的记录，在接种SARS-CoV-2 mRNA疫苗后出现了继发于疫苗的慢性、症状轻微或轻微的特发性血小板减少性紫癜（ITP）。患者接受了BNT162b2 mRNA疫苗的第一剂和第二剂（2021年6月），第一剂加强针mRNA-1273（2021年11月），以及第二剂加强针BNT162b2 mRNA疫苗（2022年6月）。每次疫苗接种后均记录到血小板减少。在实施皮质类固醇治疗后，患者病情有所改善。然而，血小板减少的周期性发作直至2023年8月（平均血小板计数：103 x10^9个/升）仍有记录。